Shanghai OPM Biosciences Co., Ltd. Class A

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A carries a market capitalization of 5.93B, placing it among publicly traded companies globally. Its enterprise value stands at 5.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai OPM Biosciences Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A has 142.17M shares outstanding.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 37.26. The price-to-sales ratio is 8.22, and the price-to-book ratio stands at 1.89.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A trades at an EV/EBITDA multiple of 36.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.31 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.00B versus a market cap of 5.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A maintains a current ratio of 4.80, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.78, indicating elevated leverage, while an interest coverage ratio of 28.04 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A posted a return on equity (ROE) of 5.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.88 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.60, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.29, useful for judging operating efficiency across full business cycles. The company generates approximately 1.77M in revenue per employee across its workforce of 357.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.73 indicates how many times Shanghai OPM Biosciences Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A recorded 1.21M in income tax expense. That works out to an effective tax rate of 0.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 137.46M, leaving 139.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Shanghai OPM Biosciences Co., Ltd. Class A's stock has gained approximately 2.57% over the past 52 weeks. The 50-day moving average sits at 64.73, while the 200-day moving average is 52.55.

Over the twelve months ended June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A generated 631.15M in revenue and converted that into 139.18M in net income, yielding earnings per share of 0.59. EBITDA reached 137.57M, while operating income came in at 88.52M.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A holds 1.18B in cash and equivalents against 244.45M in total debt, resulting in a net debt position of -979.33M. Total book value stands at 3.14B, with working capital of 1.35B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A posted a gross margin of 46.26, reflecting its pricing power and cost economics. The operating margin of 14.02 and net profit margin of 22.05 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -5.02, meaning Shanghai OPM Biosciences Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shanghai OPM Biosciences Co., Ltd. Class A's most recent stock split took place on May 12, 2023 with a 5:7 split ratio.

As of June 30, 2026, Shanghai OPM Biosciences Co., Ltd. Class A has an Altman Z-Score of 6.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.